摘要
趋化因子受体4(CXCR4)及其配体CXCL12与多种肿瘤组织的发生、发展密切相关,目前已经发现其至少存在于23种肿瘤组织中。CXCL12-CXCR4生物轴与肿瘤细胞的增殖、浸润、血管新生及转移过程密切相关。动物实验显示,CXCR4是肿瘤靶向治疗的重要靶点。然而,CXCR4也同时参与机体的胚胎发育、内环境稳定以及炎性反应。因此,研究特异性的CXCR4拮抗剂是开发以CX-CR4为靶点的新型肿瘤治疗方法的关键。
It has been showed that CXCR4 and its ligand CXCL12 are closely related to the growth and spread of cancer,and have been found in at least 23 different cancers. CXCLI2-CXCR4 axis plays a signifi- cant role in proliferation,infilatration, angiogenesis and metastatis. Animal experiments show that CXCR4 is an important target of targeted treatment. However, CXCR4 and its ligand are also widely expressed in a num- ber of embryonic development, homeostatic and inflammatory situations. Therefore, how to found the specific CXCR4 antagonists is the key to use CXCR4 therapeutic target in human cancer therapy.
出处
《医学综述》
2013年第11期1976-1978,共3页
Medical Recapitulate
